Edgar Filing: Atara Biotherapeutics, Inc. - Form 4

Washington, D.C. 20549Number:Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See InstructionSTATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESKumber: Expires:Jan Expires:Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, 30(h) of the Investment Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940Expires:									3235-0287 January 31, 2005 average rs per		
1(b). (Print or Type R	Responses)										
Haqq Christopher Symbol				r Name and Ticker or Trading iotherapeutics, Inc. [ATRA]				5. Relationship of Reporting Person(s) to Issuer			
				Earliest Transaction Day/Year)				(Check all applicable) <u></u> Director <u>X_</u> Officer (give title <u></u> 10% Owner below) Other (specify below) Chief Medical Officer			
Filed(Mont				ndment, Date Original th/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
SOUTH SA	N O, CA 94080							Person		r . c	
(City)	(State) (A	Zip)	Table I	- Non-De	erivative Se	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if T C //Year) (1		n(A) or Dis (D) (Instr. 3, 4 Amount	posed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	02/09/2016			А	55,900 (1)	А	\$0	297,619	D		
Common Stock								17,312	I	See footnote (2)	
Common Stock								2,688	Ι	See footnote (3)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of
information contained in this form are not
required to respond unless the formSEC 1474
(9-02)

Edgar Filing: Atara Biotherapeutics, Inc. - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. 6. Date Exercisable onNumber Expiration Date of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Title a Amount o Underlyin Securities (Instr. 3 a	of ng s	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	or Title Nu of	umber		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Haqq Christopher 701 GATEWAY BOULEVARD SUITE 200 SOUTH SAN FRANCISCO, CA 94080			Chief Medical Officer				
Signatures							
/s/ Tina Gullotta, Attorney-in-Fact for Chri Haqq	02/11/2016						
<u>**</u> Signature of Reporting Person		Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant (1)date, subject to the reporting person's continuous service.

- (2) The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- (3) The shares are held by The Havenside Trust, of which the Reporting Person is trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.